Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease
Factors that influence response to drug treatment are of increasing importance. We report an analysis of genetic factors affecting response to cholinesterase inhibitor therapy in 165 subjects with Alzheimer's disease (AD). The presence of apolipoprotein E ɛ4 ( APOE ɛ4 ) allele was associated wi...
Gespeichert in:
| Veröffentlicht in: | The pharmacogenomics journal 2011-12, Vol.11 (6), p.444-450 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 450 |
|---|---|
| container_issue | 6 |
| container_start_page | 444 |
| container_title | The pharmacogenomics journal |
| container_volume | 11 |
| creator | Patterson, C E Todd, S A Passmore, A P |
| description | Factors that influence response to drug treatment are of increasing importance. We report an analysis of genetic factors affecting response to cholinesterase inhibitor therapy in 165 subjects with Alzheimer's disease (AD). The presence of apolipoprotein E ɛ4 (
APOE ɛ4
) allele was associated with early and late cognitive response to cholinesterase inhibitor treatment in mild AD (Mini-Mental State Examination (MMSE) ⩾21) (
P |
| doi_str_mv | 10.1038/tpj.2010.61 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_905680656</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A273787544</galeid><sourcerecordid>A273787544</sourcerecordid><originalsourceid>FETCH-LOGICAL-c480t-40d5d216215ccebd70953390f4779f5bf146e653543c99b319854260979396c3</originalsourceid><addsrcrecordid>eNp9kk1v1DAQhiMEoqVw4o4sOBQJdvF34uOq2gJSJS49cIscZ7zrVWIH24u0_B_-J063fFUF-WCP53nHM9ZbVc8JXhLMmnd52i0pLpEkD6pTwmu2IETghzdnvKBSfT6pnqS0w5hIUjePqxOKJedC0tPq-9paMBkFi_QUBjeFKYYMzqM10r5H3T4f4mEw25LzkDJEnQBtwId8mCCh4JEJG--y-wooQpqCL_kc0B2F81vXuRwiyhF0HsFnpDPqXXk-zkHKejPXs2g1fNuCGyGep5JPUORPq0dWDwme3e5n1fXl-vriw-Lq0_uPF6urheENzguOe9FTIikRxkDX11gJxhS2vK6VFZ0lXIIUTHBmlOoYUY3gVGJVK6akYWfV-bFs-YMv-9J7O7pkYBi0h7BPrcJCNlgKWcjX_yUJxk3DGqpoQV_eQXdhH30ZY66HS4-qLtCrf0FUclJjTMUf1EYP0DpvQ47azC-3K1qzuqkF54Va3kOV1cPoTPBgXbn_S_DmKDAxpBTBtlN0o46HMkY7W6wtFmtni7WSFPrFbav7boT-F_vTUwV4ewRSSfkNxN-z3FfvB1IB2ws</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2641700257</pqid></control><display><type>article</type><title>Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Patterson, C E ; Todd, S A ; Passmore, A P</creator><creatorcontrib>Patterson, C E ; Todd, S A ; Passmore, A P</creatorcontrib><description>Factors that influence response to drug treatment are of increasing importance. We report an analysis of genetic factors affecting response to cholinesterase inhibitor therapy in 165 subjects with Alzheimer's disease (AD). The presence of apolipoprotein E ɛ4 (
APOE ɛ4
) allele was associated with early and late cognitive response to cholinesterase inhibitor treatment in mild AD (Mini-Mental State Examination (MMSE) ⩾21) (
P
<0.01). In moderate-to-severe AD (MMSE ⩽15), presence of the
BCHE-K
variant was associated with late response to cholinesterase inhibitor treatment (
P
=0.02). Testing for
APOE
and
BCHE
genotypes may be useful in therapeutic decision making.</description><identifier>ISSN: 1470-269X</identifier><identifier>EISSN: 1473-1150</identifier><identifier>DOI: 10.1038/tpj.2010.61</identifier><identifier>PMID: 20644562</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/208/727 ; 631/378/2649 ; 692/699/375/365/1283 ; 692/700/565/1436 ; Aged ; Aged, 80 and over ; Alzheimer Disease - drug therapy ; Alzheimer Disease - genetics ; Alzheimer Disease - psychology ; Alzheimer's disease ; Apolipoprotein E ; Apolipoprotein E4 - genetics ; Apolipoproteins ; Biomedical and Life Sciences ; Biomedicine ; Butyrylcholinesterase - genetics ; Cholinesterase inhibitors ; Cholinesterase Inhibitors - therapeutic use ; Cognition ; Cognitive ability ; Decision making ; Diagnosis ; Dosage and administration ; Drug therapy ; Enzyme inhibitors ; Female ; Gene Expression ; Genetic analysis ; Genetic factors ; Genotype ; Genotypes ; Human Genetics ; Humans ; Identification and classification ; Male ; Middle Aged ; Neurodegenerative diseases ; Oncology ; original-article ; Pharmacotherapy ; Properties ; Psychological Tests ; Psychopharmacology</subject><ispartof>The pharmacogenomics journal, 2011-12, Vol.11 (6), p.444-450</ispartof><rights>Macmillan Publishers Limited 2011</rights><rights>COPYRIGHT 2011 Nature Publishing Group</rights><rights>Macmillan Publishers Limited 2011.</rights><rights>Copyright Nature Publishing Group Dec 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c480t-40d5d216215ccebd70953390f4779f5bf146e653543c99b319854260979396c3</citedby><cites>FETCH-LOGICAL-c480t-40d5d216215ccebd70953390f4779f5bf146e653543c99b319854260979396c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20644562$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Patterson, C E</creatorcontrib><creatorcontrib>Todd, S A</creatorcontrib><creatorcontrib>Passmore, A P</creatorcontrib><title>Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease</title><title>The pharmacogenomics journal</title><addtitle>Pharmacogenomics J</addtitle><addtitle>Pharmacogenomics J</addtitle><description>Factors that influence response to drug treatment are of increasing importance. We report an analysis of genetic factors affecting response to cholinesterase inhibitor therapy in 165 subjects with Alzheimer's disease (AD). The presence of apolipoprotein E ɛ4 (
APOE ɛ4
) allele was associated with early and late cognitive response to cholinesterase inhibitor treatment in mild AD (Mini-Mental State Examination (MMSE) ⩾21) (
P
<0.01). In moderate-to-severe AD (MMSE ⩽15), presence of the
BCHE-K
variant was associated with late response to cholinesterase inhibitor treatment (
P
=0.02). Testing for
APOE
and
BCHE
genotypes may be useful in therapeutic decision making.</description><subject>631/208/727</subject><subject>631/378/2649</subject><subject>692/699/375/365/1283</subject><subject>692/700/565/1436</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - genetics</subject><subject>Alzheimer Disease - psychology</subject><subject>Alzheimer's disease</subject><subject>Apolipoprotein E</subject><subject>Apolipoprotein E4 - genetics</subject><subject>Apolipoproteins</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Butyrylcholinesterase - genetics</subject><subject>Cholinesterase inhibitors</subject><subject>Cholinesterase Inhibitors - therapeutic use</subject><subject>Cognition</subject><subject>Cognitive ability</subject><subject>Decision making</subject><subject>Diagnosis</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Enzyme inhibitors</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Genetic analysis</subject><subject>Genetic factors</subject><subject>Genotype</subject><subject>Genotypes</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Identification and classification</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neurodegenerative diseases</subject><subject>Oncology</subject><subject>original-article</subject><subject>Pharmacotherapy</subject><subject>Properties</subject><subject>Psychological Tests</subject><subject>Psychopharmacology</subject><issn>1470-269X</issn><issn>1473-1150</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kk1v1DAQhiMEoqVw4o4sOBQJdvF34uOq2gJSJS49cIscZ7zrVWIH24u0_B_-J063fFUF-WCP53nHM9ZbVc8JXhLMmnd52i0pLpEkD6pTwmu2IETghzdnvKBSfT6pnqS0w5hIUjePqxOKJedC0tPq-9paMBkFi_QUBjeFKYYMzqM10r5H3T4f4mEw25LzkDJEnQBtwId8mCCh4JEJG--y-wooQpqCL_kc0B2F81vXuRwiyhF0HsFnpDPqXXk-zkHKejPXs2g1fNuCGyGep5JPUORPq0dWDwme3e5n1fXl-vriw-Lq0_uPF6urheENzguOe9FTIikRxkDX11gJxhS2vK6VFZ0lXIIUTHBmlOoYUY3gVGJVK6akYWfV-bFs-YMv-9J7O7pkYBi0h7BPrcJCNlgKWcjX_yUJxk3DGqpoQV_eQXdhH30ZY66HS4-qLtCrf0FUclJjTMUf1EYP0DpvQ47azC-3K1qzuqkF54Va3kOV1cPoTPBgXbn_S_DmKDAxpBTBtlN0o46HMkY7W6wtFmtni7WSFPrFbav7boT-F_vTUwV4ewRSSfkNxN-z3FfvB1IB2ws</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Patterson, C E</creator><creator>Todd, S A</creator><creator>Passmore, A P</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20111201</creationdate><title>Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease</title><author>Patterson, C E ; Todd, S A ; Passmore, A P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c480t-40d5d216215ccebd70953390f4779f5bf146e653543c99b319854260979396c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>631/208/727</topic><topic>631/378/2649</topic><topic>692/699/375/365/1283</topic><topic>692/700/565/1436</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - genetics</topic><topic>Alzheimer Disease - psychology</topic><topic>Alzheimer's disease</topic><topic>Apolipoprotein E</topic><topic>Apolipoprotein E4 - genetics</topic><topic>Apolipoproteins</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Butyrylcholinesterase - genetics</topic><topic>Cholinesterase inhibitors</topic><topic>Cholinesterase Inhibitors - therapeutic use</topic><topic>Cognition</topic><topic>Cognitive ability</topic><topic>Decision making</topic><topic>Diagnosis</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Enzyme inhibitors</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Genetic analysis</topic><topic>Genetic factors</topic><topic>Genotype</topic><topic>Genotypes</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Identification and classification</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neurodegenerative diseases</topic><topic>Oncology</topic><topic>original-article</topic><topic>Pharmacotherapy</topic><topic>Properties</topic><topic>Psychological Tests</topic><topic>Psychopharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Patterson, C E</creatorcontrib><creatorcontrib>Todd, S A</creatorcontrib><creatorcontrib>Passmore, A P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest - Health & Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Biological Science Journals</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The pharmacogenomics journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Patterson, C E</au><au>Todd, S A</au><au>Passmore, A P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease</atitle><jtitle>The pharmacogenomics journal</jtitle><stitle>Pharmacogenomics J</stitle><addtitle>Pharmacogenomics J</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>11</volume><issue>6</issue><spage>444</spage><epage>450</epage><pages>444-450</pages><issn>1470-269X</issn><eissn>1473-1150</eissn><abstract>Factors that influence response to drug treatment are of increasing importance. We report an analysis of genetic factors affecting response to cholinesterase inhibitor therapy in 165 subjects with Alzheimer's disease (AD). The presence of apolipoprotein E ɛ4 (
APOE ɛ4
) allele was associated with early and late cognitive response to cholinesterase inhibitor treatment in mild AD (Mini-Mental State Examination (MMSE) ⩾21) (
P
<0.01). In moderate-to-severe AD (MMSE ⩽15), presence of the
BCHE-K
variant was associated with late response to cholinesterase inhibitor treatment (
P
=0.02). Testing for
APOE
and
BCHE
genotypes may be useful in therapeutic decision making.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>20644562</pmid><doi>10.1038/tpj.2010.61</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-269X |
| ispartof | The pharmacogenomics journal, 2011-12, Vol.11 (6), p.444-450 |
| issn | 1470-269X 1473-1150 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_905680656 |
| source | MEDLINE; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | 631/208/727 631/378/2649 692/699/375/365/1283 692/700/565/1436 Aged Aged, 80 and over Alzheimer Disease - drug therapy Alzheimer Disease - genetics Alzheimer Disease - psychology Alzheimer's disease Apolipoprotein E Apolipoprotein E4 - genetics Apolipoproteins Biomedical and Life Sciences Biomedicine Butyrylcholinesterase - genetics Cholinesterase inhibitors Cholinesterase Inhibitors - therapeutic use Cognition Cognitive ability Decision making Diagnosis Dosage and administration Drug therapy Enzyme inhibitors Female Gene Expression Genetic analysis Genetic factors Genotype Genotypes Human Genetics Humans Identification and classification Male Middle Aged Neurodegenerative diseases Oncology original-article Pharmacotherapy Properties Psychological Tests Psychopharmacology |
| title | Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T15%3A12%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20apolipoprotein%20E%20and%20butyrylcholinesterase%20genotypes%20on%20cognitive%20response%20to%20cholinesterase%20inhibitor%20treatment%20at%20different%20stages%20of%20Alzheimer's%20disease&rft.jtitle=The%20pharmacogenomics%20journal&rft.au=Patterson,%20C%20E&rft.date=2011-12-01&rft.volume=11&rft.issue=6&rft.spage=444&rft.epage=450&rft.pages=444-450&rft.issn=1470-269X&rft.eissn=1473-1150&rft_id=info:doi/10.1038/tpj.2010.61&rft_dat=%3Cgale_proqu%3EA273787544%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2641700257&rft_id=info:pmid/20644562&rft_galeid=A273787544&rfr_iscdi=true |